16 results about "Complete remission" patented technology

The invention discloses a longitudinal CT image-assisted rectal cancer neoadjuvant radiotherapy and chemotherapy treatment reaction evaluation device, which comprises a focus area segmentation module, a rectum focus area detection module, a rectum focus area detection module, a rectum focus area detection module, a rectum focus area detection module, a rectum focus area detection module, a rectum focus area detection module, a rectum focus area detection module and a rectum focus area detection module, obtaining a standardized three-dimensional tumor area; a feature fusion module extracts deep learning features of a focus area after segmentation at two time points before neoadjuvant radiotherapy and chemotherapy and before an operation from the three-dimensional tumor area, and performs weighted fusion on the deep learning features at the two time points through a dynamic attention weight layer to obtain longitudinal comprehensive features representing tumor treatment response changes; and the prediction module fuses the longitudinal comprehensive characteristics and clinical baseline data to construct a multi-modal prediction model, and outputs a treatment response prediction result of the rectal cancer patient on neoadjuvant chemoradiotherapy, so that the prediction accuracy of pathological complete remission of the rectal cancer patient can be improved, and the prognosis of the patient and the utilization efficiency of medical resources can be improved.

The invention provides a breast cancer adjuvant therapy pathology complete remission prediction method and electronic device.The breast cancer adjuvant therapy pathology complete remission prediction method comprises the steps that at the first stage, based on multi-time-point and multi-parameter MRI images of a patient before and after adjuvant therapy, the breast cancer adjuvant therapy pathology complete remission prediction result is obtained; training an image feature encoder with a tumor dynamic change identification capability through a dynamic supervision pre-training mode; and a second stage of constructing a multi-modal deep fusion network based on the image feature encoder to integrate the image features, radiomics features and clinical pathological features of the patient, and outputting a prediction result of complete pathology remission, the radiomics features being extracted from the MRI image. And the purposes of high precision and strong generalization capability are achieved.

The invention relates to application of a PARP inhibitor in cancer treatment, in particular to application of the PARP inhibitor in ovarian cancer maintenance treatment. More specifically, the present invention provides a maintenance therapy for an ovarian cancer patient comprising administering an effective amount of 5-fluoro-1-(4-fluoro-3-(4-(pyrimidin-2-yl) piperazine-1-carbonyl) benzyl) quinazoline-2, 4 (1H, 3H)-dione, a hydrate or a pharmaceutically acceptable salt thereof, to an ovarian cancer patient who has undergone a first-line platinum-containing regimen treatment and achieves complete or partial remission, or a pharmaceutical composition containing 5-fluoro-1-(4-fluoro-3-(4-(pyrimidin-2-yl) piperazine-1-carbonyl) benzyl) quinazoline-2, 4 (1H, 3H)-dione, a hydrate thereof, or a pharmaceutically acceptable salt thereof, or a medicament containing the pharmaceutical composition.

The invention discloses Fe (at) MoS2 hydrogel for sensitizing immunotherapy and a preparation method of the Fe (at) MoS2 hydrogel. The hydrogel comprises ferrous sulfate, molybdenum disulfide and a hyaluronic acid hydrogel matrix. The hydrogel can continuously release iron ions in a tumor slightly acidic environment, Fe is reduced into Fe by utilizing the catalytic action of MoS, and circular supply of Fe is realized, so that tumor cells are efficiently and enduringly induced to generate ferroptosis. More importantly, it is found that the Fe-coated MoShydrogel can specifically up-regulate expression of IL-36 gamma and CXCL2 in a tumor microenvironment for the first time, and by activating an IL36 gamma / CXCL2 / CXCR2 signal axis, mononuclear macrophages are recruited and remodeled, and the immunosuppression microenvironment is reversed. In-vivo experiments show that when the hydrogel is combined with an immune checkpoint inhibitor (such as an alphaPD-1 antibody), a remarkable synergistic anti-tumor effect can be generated, and the complete remission rate is greatly improved.

The invention provides a use of a marker or a combination thereof in preparation of a product for prediction, diagnosis or auxiliary diagnosis of measurable residual diseases, the measurable residual diseases occur after clinical complete remission of acute myelogenous leukemia patients, and the marker or the combination thereof comprises a C-X-C chemokine receptor 4 gene. According to the method, a multi-parameter flow sorting technology is adopted, leukemia cell populations are separated from bone marrow samples of patients in the first diagnosis stage and the AML MRD stage, and a sufficient number of residual disease cells are successfully captured through a single cell transcriptome sequencing technology. The CXCR4 low-expression cell is identified to be capable of being used as a common marker of an MRD cell, and is verified in a clinical AML patient specimen. And an innovative scheme is provided for MRD monitoring of AML patients lacking clear molecular markers. And meanwhile, a CXCR4 low-expression cell is provided as a function substitution model of the MRD cell, so that the technical limitation of insufficient residual cells in the traditional research is broken through, and a reliable research system is established for systematically exploring the biological characteristics of the MRD cell.

Methods and uses of immunoconjugates that bind to CD123 (e.g., pivekimab sunirine) in patients with acute myeloid leukemia (AML) are provided. Such immunoconjugates can be used as monotherapies or can be used in combination with BCL-2 inhibitors (e.g., venetoclax), and / or hypomethylating agents (e.g., azacitidine or decitabine) to prepare patients with AML for hematopoietic stem cell transplant and / or to achieve complete remissions in patients with AML, including those with poor prognostic markers.

The application relates to the technical field of detection kits, in particular to application of miRNA-142-3p in predicting treatment responsiveness of IgA nephropathy. The application finds that urine miRNA-142-3p is related to a complete remission group after treatment of IgA nephropathy patients and a non-complete remission group after treatment. More specifically, the application finds that the urine miRNA-142-3p expression amount of the non-complete remission group after treatment of the IgA nephropathy patients is significantly higher than that of the complete remission group. Moreover, the relative expression amount of miRNA-142-3p is used as a single index for detection, and the AUC is 0.847 (0.769, 0.925), which is similar to 0.84 (95% CI 0.81-0.88) of a current invasive method for predicting treatment responsiveness of IgA nephropathy in kidney tissues.

The present application provides a set of complete innovative technical solutions from target discovery to treatment intervention for the immune escape and drug resistance recurrence problems existing in the clinical treatment of multiple myeloma (MM). It is found that Siglec7 is mainly highly expressed on the surface of NK cells, and the proportion and expression intensity of Siglec7 positive NK cells are significantly higher than those of complete remission and non-tumor controls; further, Siglec7 monoclonal antibody is prepared, and when the anti-Siglec7+CD38 monoclonal antibody (such as daratumumab) is used, a significant synergistic anti-tumor effect can be produced in vitro and in vivo. The technical solution completely constructs the research and development chain of "marker discovery-target verification-drug development-treatment application", and provides a new target, specific antibody drug and innovative combined drug regimen for the precise diagnosis, prognosis and especially immunotherapy of refractory and relapsed patients with multiple myeloma, which has great clinical transformation value and market prospect.

The invention provides a treatment response model for acute myelogenous leukemia (AML) accompanied with myelodysplastic syndrome related genetic abnormality (MRGA) and application thereof, and the model combines clinical data, cytogenetics and molecular biology data of patients. Variables significantly related to the complete remission rate of the patient are screened out through Lasso regression and Cox multivariable regression analysis, a treatment response model for predicting the complete remission rate is constructed based on the variables, and a combined scoring system formed by the treatment response model and a constructed survival risk scoring model is used for predicting the response of the patient to induced treatment and 1-3-year survival prognosis. And an individualized basis is provided for clinical treatment decision-making of the AML patient.

The invention discloses a method, a device, equipment and a medium for predicting the reaching of pCR of neoadjuvant chemotherapy of triple negative breast cancer, and relates to the technical field of medical data processing, and the method comprises the following steps: obtaining clinical pathological characteristics of a to-be-detected object and peripheral blood counting data before neoadjuvant chemotherapy; the peripheral blood count data comprises neutrophil count, lymphocyte count, platelet count and mononuclear cell count; the clinical pathological characteristics comprise a T staging characteristic, an N staging characteristic and a Ki-67 characteristic; determining a target biomarker related to pathologic complete remission pCR prediction based on the peripheral blood count data, and calculating an immune inflammation score according to the target biomarker; the clinical pathological features and the immune inflammation scores are processed through a trained XGB model, and a pCR prediction result of the to-be-detected object is obtained; and the XGB model is used for capturing a nonlinear relationship and an interaction effect among the data. According to the invention, the problem of poor detection timeliness can be avoided, and the pCR prediction accuracy is improved at the same time.

The application discloses a kind of longitudinal CT image auxiliary evaluation rectal cancer neoadjuvant radiotherapy treatment response device, the device includes focus area segmentation module obtains rectal cancer patient before neoadjuvant radiotherapy and before surgery CT enhanced image, carries out rectal focus area automatic segmentation to target image after pre-processing, obtains standardized three-dimensional tumor area;Feature fusion module extracts the deep learning feature of segmented focus area before neoadjuvant radiotherapy and before surgery from three-dimensional tumor area respectively, two time points deep learning features are weighted and fused by dynamic attention weight layer, obtain longitudinal comprehensive features representing tumor treatment response change;Predictive module fuses longitudinal comprehensive features and clinical baseline data to construct multimodal prediction model, outputs the treatment response prediction result of rectal cancer patient to neoadjuvant radiotherapy, can improve the prediction accuracy of rectal cancer patient pathological complete remission, improve patient prognosis and medical resource utilization efficiency.

This invention discloses a neoadjuvant therapy efficacy prediction system and method based on a multimodal large model and breast ultrasound, belonging to the field of medical artificial intelligence technology. The method includes: acquiring pre-treatment ultrasound images of patients and multidimensional heterogeneous text data including past medical history, ultrasound reports, and pathological indicators; unifying the format using serialization technology and inputting it into a pre-trained multimodal large model; utilizing the model's powerful cross-modal sequence modeling capabilities to mine deep implicit associations between images and medical history, and outputting a predicted probability value for pathological complete remission (pCR). The system simultaneously outputs image heatmaps and textual decision attribution prompts. This invention achieves high-precision end-to-end personalized efficacy prediction and possesses strong clinical interpretability.

This invention belongs to the field of biomedical technology and discloses exosomes derived from induced pluripotent stem cells (iPSCs) with anti-tumor activity and their application in enhancing CAR-T cell therapy. This invention is the first to discover that iPSC-derived exosomes possess inherent anti-tumor activity by directly inhibiting tumor cell proliferation, inducing apoptosis, and inhibiting migration, with a yield hundreds of times higher than that of traditional cell-derived exosomes. Through genetic engineering, the surface of the exosomes is made to display a bispecific single-chain variable fragment against PD-1 / MSLN and loaded with indole-3-propionic acid, constructing a multifunctional therapeutic platform. This platform, administered via nebulized inhalation, achieved a 66.7% complete remission rate, a 100% 80-day survival rate, and an 83.3% resistance to tumor re-challenge in an orthotopic lung cancer model when combined with CAR-T therapy, significantly outperforming existing treatment strategies. This invention provides an innovative enhancement strategy for CAR-T cell therapy in solid tumors and has significant clinical translational value.

The invention relates to a model construction method and system for predicting complete remission of proteinuria of children IgA nephropathy and a storage medium, and belongs to the field of medical detection and disease prognosis prediction. At least one of the problems of insufficient accuracy, high clinical misjudgment risk, poor applicability of an adult model in a child group and the like of an existing prediction method for relieving proteinuria of the child IgA nephropathy is solved. The construction method comprises the following steps: acquiring clinical data of a child IgA nephropathy patient; and preprocessing the clinical data, and constructing a prediction model through Cox proportional risk regression analysis based on the preprocessed data. According to the invention, accurate prediction of proteinuria remission of children IgA nephropathy is realized, and reference is provided for clinical individualized treatment.

The present invention relates to the combined use of an interleukin-2 analog or a long-acting conjugate thereof and a CTLA-4 antagonist, for the prevention or treatment of cancer, and a pharmaceutical composition comprising same. When administered in combination with the CTLA-4 antagonist, the interleukin-2 analog or the long-acting conjugate thereof exhibits excellent tumor growth inhibition effects and induces complete remission while also reducing side effects, and thus can be used as an excellent anti-cancer therapeutic agent.